ATE280833T1 - Kationische lipide/dns komplexe zum zielen von genen - Google Patents

Kationische lipide/dns komplexe zum zielen von genen

Info

Publication number
ATE280833T1
ATE280833T1 AT96919212T AT96919212T ATE280833T1 AT E280833 T1 ATE280833 T1 AT E280833T1 AT 96919212 T AT96919212 T AT 96919212T AT 96919212 T AT96919212 T AT 96919212T AT E280833 T1 ATE280833 T1 AT E280833T1
Authority
AT
Austria
Prior art keywords
cationic lipid
complexes
dna complexes
methods
genes
Prior art date
Application number
AT96919212T
Other languages
English (en)
Inventor
Cori M Gorman
Molly Mcclarrinon
Original Assignee
Valentis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valentis Inc filed Critical Valentis Inc
Application granted granted Critical
Publication of ATE280833T1 publication Critical patent/ATE280833T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT96919212T 1995-06-07 1996-06-07 Kationische lipide/dns komplexe zum zielen von genen ATE280833T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/485,005 US5830878A (en) 1995-06-07 1995-06-07 Cationic lipid: DNA complexes for gene targeting
PCT/US1996/009526 WO1996040962A1 (en) 1995-06-07 1996-06-07 Cationic lipid:dna complexes for gene targeting

Publications (1)

Publication Number Publication Date
ATE280833T1 true ATE280833T1 (de) 2004-11-15

Family

ID=23926552

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919212T ATE280833T1 (de) 1995-06-07 1996-06-07 Kationische lipide/dns komplexe zum zielen von genen

Country Status (7)

Country Link
US (2) US5830878A (de)
EP (1) EP0832270B1 (de)
AT (1) ATE280833T1 (de)
AU (1) AU698318B2 (de)
CA (1) CA2223923A1 (de)
DE (1) DE69633725T2 (de)
WO (1) WO1996040962A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052603A2 (en) * 1997-05-23 1998-11-26 Schweiz. Serum- & Impfinstitut Bern An influenza enveloped dna vaccine
US5674908A (en) * 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
EP0941066B1 (de) * 1996-08-26 2003-10-29 Transgene S.A. Kationische lipid-nukleinsäure komplexe
US7384923B2 (en) * 1999-05-14 2008-06-10 Lipoxen Technologies Limited Liposomes
EP0938298B1 (de) * 1996-09-13 2002-12-04 Lipoxen Technologies Limited Liposomenzusammensetzung
US5958894A (en) * 1997-04-04 1999-09-28 Megabios Corporation Amphiphilic biguanide derivatives
US6235310B1 (en) 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
US6121457A (en) 1997-11-14 2000-09-19 Megabios Corporation Compositions and methods using novel substituted imidazolium lipids
JP2001523480A (ja) 1997-11-20 2001-11-27 バイカル インコーポレイテッド サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
CA2350882C (en) 1998-11-12 2011-02-22 Life Technologies Corporation Transfection reagents
AUPQ259399A0 (en) 1999-09-01 1999-09-23 Lustre Investments Pte Ltd Therapeutic agents
KR100373845B1 (ko) * 2000-09-21 2003-02-26 굿젠 주식회사 유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법
US20030096414A1 (en) * 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
WO2009038779A2 (en) * 2007-09-19 2009-03-26 University Of Tennessee Research Foundation Methods and compositions for inhibiting undesirable cellular proliferation by targeted liposome delivery of active agents
US8044215B2 (en) * 2009-04-29 2011-10-25 Juvaris Biotherapeutics, Inc. Methods for the preparation of amphillic nitrogen containing imidazolinium derivative compounds
SI2654785T1 (sl) * 2010-12-22 2019-06-28 Bayer Intellectual Property Gmbh Ojačan imunski odziv pri govejih vrstah
CA2940794C (en) 2014-02-28 2022-05-31 Bayer Animal Health Gmbh Immunostimulatory plasmids
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
UA123265C2 (uk) * 2015-05-04 2021-03-10 Байєр Енімал Хелс Гмбх Спосіб одержання амфіфільних сполук імідазолінію
CN121102495A (zh) * 2025-11-17 2025-12-12 联合钠米(天津)科技有限公司 一种基于二烃基咪唑阳离子脂质的核酸药物制剂及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503372A (ja) * 1992-01-23 1995-04-13 バイカル・インコーポレイテッド 生体外遺伝子導入
US5705655A (en) * 1992-12-17 1998-01-06 Megabios Corporation Amphiphilic nitrogen containing imidazolinium derivative compounds and uses
ATE221575T1 (de) * 1993-05-10 2002-08-15 Univ Michigan Gentransfer zu den pankreatischen epithelzellen
KR960705771A (ko) * 1993-11-24 1996-11-08 벤자민 에프 맥그로우 구아니딘의 양쪽친화성 유도체(amphiphilic derivatives of guanidine)
KR960705798A (ko) * 1993-11-24 1996-11-08 벤자민 에프 맥그로우 피페라진의 양쪽친화성 유도체(amphiphilic derivatives of piperazine)
US5830878A (en) * 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting

Also Published As

Publication number Publication date
US6344446B1 (en) 2002-02-05
AU6160996A (en) 1996-12-30
US5830878A (en) 1998-11-03
EP0832270A1 (de) 1998-04-01
DE69633725T2 (de) 2005-03-17
EP0832270B1 (de) 2004-10-27
AU698318B2 (en) 1998-10-29
WO1996040962A1 (en) 1996-12-19
CA2223923A1 (en) 1996-12-19
DE69633725D1 (de) 2004-12-02

Similar Documents

Publication Publication Date Title
DE69633725D1 (de) Kationische lipide/dns komplexe zum zielen von genen
KR960703170A (ko) 안티센스 올리고뉴클레오티드 및 인간면역결핍바이러스감염에서 그것의 치료적이용(antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection)
FR2712812B1 (fr) Composition pour la production de produits thérapeutiques in vivo.
CY1105475T1 (el) Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων
HUP0002454A2 (hu) D-Vitamin-molekularésszel rendelkező konjugátumok és ilyen konjugátumokat tartalmazó gyógyászati készítmények
TR199902529T2 (xx) Etkinle�tirilmi� protein C form�lasyonlar�.
DE69531332D1 (de) Klonierung und Expression eines Gens, das Bryodin 1 aus Bryonia dioica kodiert
ATE411333T1 (de) Invertierte chimäre und hybrid-oligonukleotide
EP0939621A4 (de) Hemmung der bcl-2 protein expression durch liposomale antisense-oligodeoxynukleotide
WO1999033982A3 (en) Human genes and gene expression products i
WO1999058675A3 (en) Human genes and gene expression products v
WO1999038972A8 (en) Human genes and gene expression products ii
AU3368497A (en) Human dnase i hyperactive variants
DE60222790D1 (de) Dendrimere zur verwendung in gezielter verabreichung
RU95104940A (ru) Способ введения в олигонуклеотид алкилфосфонотиоатной или арилфосфонотиоатной межнуклеотидной связи, способ получения олигонуклеотида, олигонуклеотиды, способ ингибирования генной экспрессии, способ лечения
IL141141A0 (en) Targeting pharmaceutical agents to injured tissues
FI963103A0 (fi) Ei-virusvektori
DE69709407D1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
EP0769968A4 (de) Retrovirale vektoren, die von gegen lyse durch menschliches serum resistenten produktionszellinien produziert werden
WO2002044320A3 (en) Human elongase genes and uses thereof
WO2022256499A3 (en) Bcma targeting trispecific proteins and methods of use
WO1999064594A8 (en) Genes and gene expression products that are differentially regulated in prostate cancer
ATE345139T1 (de) Karzinostatische wirkstoffe
SE9503117D0 (sv) Novel use of padlock probes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties